Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878605 · ClinicalTrials.gov registry record · Phase 2
Development of A Novel Anti-Hyperglycemic Agent
A Phase 2 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00878605: Clinical Trial Phase 2 study, sponsored by VA Office of Research and Development.
NCT00878605 is a Phase 2 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00878605, a Phase 2 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to test the effectiveness and safety of a new anti-diabetes drug (Cyclo-Z) for the prevention and treatment of Type 2 diabetes. This study will determine dose-dependent efficacy and safety of this new drug for the treatment of human diabetes. The Food and Drug Administration has granted approval for the use of this investigational product to be used in a study \[FDA approval (Investigational New Drug) IND #: 61,897\]. This new drug is thought to work by increasing the amount of zinc in your body, which in turn should improve your sugar metabolism. If this study successfully proves that Cyclo-Z is effective for the treatment of diabetes and is without significant side effects, a large, multi-center study of diabetic patients will then be performed.
Interventions
- DRUG Placebo
- DRUG Cyclo-Z
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-04-01 |
| Est. Completion | 2013-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00878605
The ClinicalTrials.gov registry entry for NCT00878605 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00878605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00878605 about?
NCT00878605 is a clinical study titled "Development of A Novel Anti-Hyperglycemic Agent". The purpose of this clinical trial is to test the effectiveness and safety of a new anti-diabetes drug (Cyclo-Z) for the prevention and treatment of Type 2 diabetes. This study will determine dose-dependent efficacy and safety of this new drug for the treatment of human diabetes. The Food and Drug A...
What is the current status of trial NCT00878605?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2010-04-01. Estimated completion is 2013-09-30.
What interventions are being tested in trial NCT00878605?
The interventions under investigation include: Placebo (DRUG), Cyclo-Z (DRUG).
Who is sponsoring clinical trial NCT00878605?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.